Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
QNCX Quince Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: QNCX
Price (delayed)
$1.09
Market cap
$49.56M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.39
Enterprise value
$57.44M
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence
Highlights
The net income has shrunk by 100% YoY and by 7% QoQ
The EPS has dropped by 83% year-on-year and by 6% since the previous quarter
Key stats
What are the main financial stats of QNCX
Market
Valuations
Earnings
Shares outstanding
45.47M
Market cap
$49.56M
Enterprise value
$57.44M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.58
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$57.56M
Net income
-$60.71M
EBIT
-$60.61M
EBITDA
-$60.43M
Free cash flow
-$33.52M
Per share
Balance sheet
Liquidity
EPS
-$1.39
EPS diluted
-$1.39
Free cash flow per share
-$0.76
Book value per share
$0.42
Revenue per share
$0
TBVPS
$1.02
Total assets
$107.09M
Total liabilities
$88.51M
Debt
$15.65M
Equity
$18.58M
Working capital
$25.47M
Debt to equity
0.84
Current ratio
4.05
Quick ratio
3.78
Net debt/EBITDA
-0.13
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-50.3%
Return on equity
-172.7%
Return on invested capital
-101.7%
Return on capital employed
-61.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
QNCX stock price
How has the Quince Therapeutics stock price performed over time
Intraday
3.81%
1 week
2.83%
1 month
2.83%
1 year
27.95%
YTD
-41.71%
QTD
-18.05%
Financial performance
How have Quince Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$57.56M
Net income
-$60.71M
Gross margin
N/A
Net margin
N/A
QNCX's operating income has dropped by 101% year-on-year and by 8% since the previous quarter
The net income has shrunk by 100% YoY and by 7% QoQ
Price vs fundamentals
How does QNCX's price correlate with its fundamentals
Growth
What is Quince Therapeutics's growth rate over time
Valuation
What is Quince Therapeutics stock price valuation
P/E
N/A
P/B
2.58
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has dropped by 83% year-on-year and by 6% since the previous quarter
The equity has shrunk by 75% YoY and by 38% QoQ
QNCX's P/B is 43% above its last 4 quarters average of 1.8 but 30% below its 5-year quarterly average of 3.7
Efficiency
How efficient is Quince Therapeutics business performance
The ROIC has dropped by 117% year-on-year and by 15% since the previous quarter
Quince Therapeutics's ROA has plunged by 108% YoY and by 18% from the previous quarter
The ROE has decreased by 49% QoQ
Dividends
What is QNCX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for QNCX.
Financial health
How did Quince Therapeutics financials performed over time
QNCX's total assets is 21% greater than its total liabilities
The quick ratio has contracted by 45% YoY and by 33% from the previous quarter
The current ratio has contracted by 43% YoY and by 33% from the previous quarter
The debt is 16% lower than the equity
The equity has shrunk by 75% YoY and by 38% QoQ
QNCX's debt to equity has surged by 71% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.